A topical peptide that gently eases the small muscle contractions behind expression lines. Small, often industry-funded studies suggest modest softening of fine lines and slight gains in skin moisture and smoothness — far milder than injectables. Whether enough passes through the skin barrier remains uncertain. Low-risk for cosmetic use; the benefit is modest, gradual, and maintenance-dependent. (Full Review)

Protocol

Formulation

5–10% leave-on serum or cream

Argireline solution applied to clean, dry skin over expression-prone areas (crow's feet, forehead, between brows)

Frequency

Twice daily

Morning and evening; rapid breakdown means the effect relies on sustained, repeated exposure

Timing

Flexible

Not light-sensitive; often applied in the morning under sunscreen. Space apart from night-time retinoids

Time to effect

Visible changes

2–4 weeks

Gradual softening of dynamic lines with consistent use; no immediate, injection-like result

Continued development

1–3 months

Effects keep developing with sustained daily application

Benefits

Medium: Reduction of dynamic expression wrinkles

Low: Improved skin hydration and reduced surface water loss; improved smoothness and elasticity; reduced oily-skin shine; cosmetic camouflage of scars and imperfections

Speculative: Preventive delay of expression-line formation; synergy with other cosmetic peptides

Contraindications

Known allergy to the peptide or product ingredients

Active facial dermatitis, broken or infected skin, or recent facial procedures

Injection of the material (not an injectable)

Pregnancy or breastfeeding (caution, limited data)

Key Interactions

Injectable neuromodulators (botulinum toxin)

Other muscle-relaxing peptides (acetyl octapeptide-3, pentapeptide-18)

Topical retinoids and exfoliating acids (retinol, adapalene, glycolic/salicylic acid)

Other cosmetic actives (vitamin C, niacinamide, copper peptides)

Risk & Side Effects

Medium: Local skin irritation, redness, and stinging

Low: Allergic contact dermatitis; periocular and eye irritation; infection or injury from unapproved injection

Speculative: Systemic toxicity

Monitoring

Marker	Target	Why
Standardized facial photography (expression lines)	Visible reduction or stabilization of dynamic lines vs. baseline	Primary way to judge cosmetic benefit
Corneometer skin hydration	Increase above personal baseline	Tracks the hydration/surface-smoothing effect
Transepidermal water loss (TEWL)	Decrease toward or below personal baseline	Indicates improved surface barrier comfort
Cutometer skin elasticity	Increase above personal baseline	Captures subtle firmness/elasticity changes
Wrinkle depth/roughness (skin-imaging camera or replica)	Reduction vs. baseline	Objective correlate of the marketed benefit

Cadence: Reassess at ~4 weeks, again at 8–12 weeks, then every 3–6 months of continued use

Qualitative Assessment

Perceived smoothness and softness of the treated skin
Self- and observer-rated appearance of crow's feet and forehead lines
Comfort and tolerance (absence of persistent redness, stinging, or itching)
Overall satisfaction and whether the visible change justifies continued use

Acetyl Hexapeptide-8 for Skin Rejuvenation

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment